MSD promotional satellite symposium at BTOG Annual Conference 2024

MSD is proud to have been the Diamond sponsor of the British Thoracic Oncology Group (BTOG) in 2024

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

BTOG 2024 summary:

At BTOG 2024 we presented two MSD-sponsored symposia, one focusing on metastatic NSCLC and the other on early-stage NSCLC.

Below, you can hear a recap of our metastatic NSCLC symposium, view our key resource for early-stage NSCLC and explore our milestone wall, which navigates through our NSCLC journey.

Progress in redefining survival expectations and lessons learnt in improving patient outcomes with immunotherapy in 1L PD-L1 ≥50% metastatic NSCLC patients

Hear from Dr Shah below, reflecting on what was presented for the metastatic NSCLC symposium.

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Key objectives:

The impact of immunotherapy and KEYTRUDA in transforming the patient journey in mNSCLC compared to the pre-IO era

The clinical evidence and treatment strategies that are licensed and reimbursed for mNSCLC patients with PD-L1 ≥50%

The patient and HCP experience, including practical lessons to improve patient care and outcomes throughout the journey

Your speaker: Dr Riyaz Shah

Consultant Medical Oncologist,

Maidstone and Tunbridge Wells NHS Trust, Kent

Dr Riyaz Shah is a Consultant Medical Oncologist at Kent Oncology Centre, Maidstone Hospital.
He qualified from Guy’s and St Thomas’ Hospitals in 1994.

Dr Shah was an Imperial Cancer Research Fund Clinical Research Fellow at the Hammersmith Hospital before completing SpR training at The Royal Marsden Hospital.

Dr Shah has been a consultant Medical Oncologist at the Kent Oncology Centre since 2006 and focuses on thoracic malignancies and clinical trials. He is a member of the BTOG steering committee and has previously served on the NCRI lung group.

For the symposium on early-stage NSCLC, The role of adjuvant immunotherapy in early-stage NSCLC, we unfortunately don’t have a recording available. However, if you would like to speak to a representative or view our indication and data for KEYNOTE-091, see links below.

If you would like to connect with an MSD representative, please e-mail us to set up an appointment:

Request an appointment

KEYNOTE-091 DATA DECK

Learn more

KEYTRUDA is the first immunotherapy to present 5-year data in 3 first-line metastatic NSCLC indications licensed in the UK^{3,8,10,12–15}

More information about KEYTRUDA in metastatic NSCLC

Abbreviations

1L, first line; ASCO, American Society of Clinical Oncology; BTOG, British Thoracic Oncology Group; ESMO, European Society for Medical Oncology; HCP, healthcare professional; IO, immuno-oncology; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; mNSCLC, metastatic non-small cell lung carcinoma; NCRI, National Cancer Research Institute; NSCLC, non-small cell lung carcinoma; PD-L1, programmed death-ligand 1, SpR, specialist registrar.

References

Reck M, et al. Presented at ESMO 2016. 7–11 October 2016. Copenhagen, Denmark. Abstract LBA8.
EMA. Keytruda. Available at: https://www.ema.europa.eu/en/documents/procedural-steps-after/keytruda-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf Accessed May 2024.
Gandhi L, et al. N Engl J Med 2018;378:2078–2092 (and supplementary appendix).
Paz-Ares L, et al. Presented at ASCO 2018. 1–5 June 2018. Chicago, Illinois, USA. Abstract 105.
NICE. Available at: https://www.nice.org.uk/guidance/ta531 Accessed: May 2024.
NICE. Available at: https://www.nice.org.uk/guidance/ta557 Accessed: May 2024.
NICE. Available at: https://www.nice.org.uk/guidance/TA600 Accessed: May 2024.
Reck M, et al. J Clin Oncol 2021;39:2339–2349.
Garassino MC, et al. Presented at ESMO 2022. 9–13 September 2022. Paris, France. Abstract 973MO.
Novello S, et al. Presented at ESMO 2022. 9–13 September 2022. Paris, France. Abstract 974MO.
O’Brien M, et al. Lancet 2022;23:1274–1286.
Garassino MC, et al. J Clin Oncol 2023:41:1992–1998.
KEYTRUDA Summary of Product Characteristics.
Paz-Ares L, et al. N Engl J Med 2018;379:2040–2051 (and supplementary appendix).
Reck M, et al. N Engl J Med 2016;375:1823–1833.

Supporting documentation:

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.

Therapeutic indications:

KEYTRUDA as monotherapy is indicted for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.¹³
KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic NSCLC in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.¹³
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.¹³
KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults.¹³
KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.¹³

MSD at BTOG 2024